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INTRODUCTION
Colon and rectal cancer are the third most common malig-
nancies worldwide [1], and the third highest cancer by 
incidence in Korea [2]. Although surgery remains one of the 
most important treatment modalities, adjuvant chemotherapy 
after resection is recommended to reduce local and systemic 
recurrence in colon cancer.
Folinic acid, fluorouracil and oxaliplatin (FOLFOX) is a che-
mo therapy regimen for colorectal cancer, made up of three 
drugs including folinic acid (leucovorin), fluorouracil (5-FU) and 
oxaliplatin. Because adding oxaliplatin to a 5-FU and leucovorin 
regimen or capecitabine is suggested to reduce the probability 
of recurrence upto 20%, FOLFOX is regarded as a standard 
adjuvant chemotherapy treatment for stage III colon cancer [3-6]. 
However, major serious adverse reactions such as anaphylaxis 
and allergic reaction, neuropathy, pulmonary toxicities, hepa-
totoxicity, cardiovascular, rhabdomyolysis, as well as minor side 
effects are reported during oxaliplatin-based che mo therapy. 
These toxicities have an impact on patient quality of life and 
sometimes restrict applications of the FOLFOX regimen.
Sinusoidal injury of the liver is a known oxaliplatin-specific Reviewed January
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Purpose: This study investigated how adding Korean red ginseng extract (KRG) to folinic acid, fluorouracil and oxaliplatin 
(FOLFOX) chemotherapy affected the rate of splenomegaly in colon cancer.
Methods: This retrospective study analyzed 42 patients who were randomly assigned to receive a FOLFOX regimen with or 
without KRG. Spleen volume change was assessed by computed tomography scans measured before surgery (presurgery 
volume) and 3 weeks after cessation of the 12th cycle of FOLFOX (postchemotherapy volume).
Results: All patients showed increased spleen volume. No difference was observed in median presurgery and 
postchemotherapy volume between the KRG and control groups. However, a ratio defined as postchemotherapy volume 
divided by presurgery volume was significantly lower in the KRG group than the control group (median, 1.38 [range, 1.0–2.8] 
in KRG group vs. median, 1.89 [range, 1.1–3.0] in control group, P = 0.028). When splenomegaly was defined as a >61% 
increase in spleen volume, the rate of splenomegaly was significantly lower in the KRG group than the control group (28.6% 
vs. 61.9%, P = 0.03). KRG consumption was inversely associated with developing splenomegaly in multivariate analysis.
Conclusion: Adding KRG during FOLFOX chemotherapy for colon cancer might protect against oxaliplatin-induced 
splenomegaly. The protective effect of Korean red ginseng should be investigated with further research.
[Ann Surg Treat Res 2018;95(3):161-167]
Key Words:  Oxaliplatin, Splenomegaly, Colonic neoplasms, Folfox protocol
162
Annals of Surgical Treatment and Research 2018;95(3):161-167
complication. The histopathological features of sinusoidal 
injury include sinusoidal dilatation and congestion, small 
vessel obliteration, hepatocyte plate disruption, parenchymal 
extinction lesions, nodular regenerative hyperplasia, peliosis, 
and veno-occlusive disease [7]. Although the direct reasons for 
sinusoidal injury after oxaliplatin-based chemotherapy are not 
well understood, initial toxic effects to sinusoidal endothelial 
cells may cause sinusoidal wall disruption, eventually leading to 
fibrotic change with sinusoidal matrix deposition [8]. A report 
found that 78% of patients showed sinusoidal obstruction, 
complicated by perisinusoidal fibrosis and veno-occlusive lesion 
after use of oxaliplatin as a preoperative chemotherapy regimen 
[8]. The rate of this kind of liver damage is relatively higher 
after use of oxaliplatin than with other kinds of chemotherapy 
agents such as Irinotecan or 5-FU/leucovorin [9,10]. 
Overman et al. [11] reported that increased spleen size 
cor rel ates with cumulative oxaliplatin dose. In addition, 
splenomegaly could be used as a simple biomarker to predict 
oxaliplatin-induced sinusoidal liver injury [11]. Other studies 
demonstrate that oxaliplatin use can cause splenomegaly in 
colorectal cancer patients [12-14]. Clinically, splenic enlargement 
might induce thrombocytopenia after long-term follow-up 
[11,13].
Robinson et al. [15] reported that FOLFOX injection via 
an intraperitoneal route induces sinusoidal dilatation and 
hepatocyte atrophy in the liver of a murine model, causing 
sinusoidal obstruction syndrome (SOS). The study showed 
that dietary supplementation with the antioxidant butylated 
hydroxyanisole prevents SOS. 
Korean red ginseng is a heat-and-steam processed product 
of Korean ginseng (Panax ginseng Meyer). Korean red ginseng 
has a variety of pharmacological activities including anti-
inflammatory and antitumor effects. Studies demonstrate that 
Korean red ginseng attenuates ethanol-induced oxidative injury 
of the liver in a murine model [16,17]. 
Based on these results, we hypothesized that Korean red 
ginseng might protect against oxaliplatin-induced liver damage. 
Considering the correlation between splenomegaly and 
sinusoidal liver injury after oxaliplatin-based chemotherapy, 
whether Korean red ginseng extract (KRG) offers benefits for 
reducing development of splenomegaly in colon cancer patients 
who receive adjuvant oxaliplatin-based chemotherapy remains 
unclear. Thus, this study investigated whether adding KRG 
to FOLFOX affected the rate of splenomegaly in colon cancer 
patients.
METHODS
Patient demographics
This retrospective study analyzed 42 patients who underwent 
surgery for adenocarcinoma of the colon and received FOLFOX 
adjuvant chemotherapy between June 2012 and June 2016. The 
patients were part of a cohort that was prospectively designed 
to evaluate the clinical efficacy of Korean red ginseng for 
breast, pancreas and colon cancer after adjuvant chemotherapy. 
Twenty-one patients were allocated into each of the 2 groups: 
the Korean red ginseng group and the control group. This 
study was a retrospective study and a subgroup analysis using 
prospectively collected data. This study was approved by 
Gangnam Severance Hospital, Yonsei University College of 
Medicine Institutional Review Board (3-2016-0287). Informed 
consent was waived for this retrospective study.
Adjuvant chemotherapy and Korean red ginseng 
consumption
All patients received 12 cycles of FOLFOX regimen. For stage 
III colon cancer, adjuvant FOLFOX chemotherapy is a standard 
chemotherapy. Patients with stage II colon cancer with high 
risk factors such as T4, obstruction or perforation in clinical 
presentation, lymphovascular invasion, retrieval of fewer than 
12 lymph nodes, or poorly differentiated histology were also 
treated with FOLFOX regimen.
Fig. 1. CT based voulmetry. Spleen 
volume was measured by manual 
calculation for CT slices and su-
mmation of bou ndaries was de-
termined by a 3-dimensional pro-
gram. 
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The dose schedule given every 2 weeks was oxaliplatin (85 
mg/m2 IV infusion of more than 2 hours on day 1), leucovorin 
(400 mg/m2 IV infusion of more than 2 hours on day 1), and 
5-FU (400 mg/m2 IV bolus injection on day 1, followed by 2,400 
mg/m2 continuous IV injection over 46 hours). A total of 12 cycles 
was planned. Antiemetic prophylaxis with 5-HT3-receptor 
antagonist was given every cycle. Patients in the Korean red 
ginseng group received a total 3 g of KRG per day during the 
chemotherapy periods. Safety of 3 g KRG intake in a day was 
already proved in a previous randomized controlled trial on the 
effect of improving blood circulation [18]. In addition, another 
prospective randomized trial investigating the immune effect of 
KRG in patients with colon cancer who had a curative resection 
and chemotherapy used daily 3 g of KRG [19]. Based on these 
previous results, the initial prospective study chose to use 3 g 
of KRG as a daily dose.
Spleen volume measurements and definition of 
splenomegaly
Spleen volume was measured by hand-tracing the organ 
outline on CT images and calculating using commercially 
available volume-measuring software (Voxel Plus 2.0; Medisys 
Co., Daejeon, Korea) (Fig. 1). The spleen outline on each 
abdominal axial image and the sum of the marked area, 
accounting for slice thickness, was used. Spleen volume was 
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Fig. 2. Receiver operating characteristic (ROC) curve. ROC 
curve revealed that the most accurate cutoff value pre-
dicting occurrence of thrombocytopenia after cessation of 
chemotherapy was Youden's index 1.612 (area under the 
curve, 0.687; sensitivity, 70.6%; specificity, 28%).
Table 1. Patient demographics 
Variable Korean red ginseng group Control group P-value
Sex
Male 10 (47.6) 12 (57.1) 0.537
Female 11 (52.4) 9 (42.9)
Age (yr) 59.6 ± 13.4 59.6 ± 9.2 0.986
Body mass index (kg/m2) 23.3 ± 2.5 23 ± 3.2 0.749
Body surface area 1.6 ± 0.2 1.6 ± 0.1 0.231
Stage
II 3 (14.3) 2 (9.5) >0.999b)
III 18 (85.7) 19 (90.5)
Tumor locationa)
Right colon 7 (33.3) 7 (33.3) >0.999
Left colon 14 (66.7) 14 (66.7)
Values are presented as number (%) or mean ± standard deviation.
a)Right colon, cecum – transverse colon; left colon, descending colon – rectosigmoid junction. b)Fisher exact test. 
Table 2. Comparison of parameters on spleen volume between the 2 groups
Variable Korean red ginseng group Control group P-value
Spleen volume (cm3)
Presurgery 132 (45–388) 141 (64–250) 0.753b)
Postchemotherapy 212 (95–533) 247 (84–564) 0.122b)
Ratio of spleen volumea) 1.38 (1.03–2.81) 1.89 (1.13–3.01) 0.028b)
Splenomegaly after final chemotherapy 6 (28.6) 13 (61.9) 0.030
Values are presented as median (range) or number (%).
a)Postchemotherapy volume/presurgery volume. b)Mann-Whitney U-test.
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measured by an investigator who was blinded to patient 
clinical data. Spleen volume was assessed twice using CT 
images performed before index surgical resection (presurgical 
volume) and 3 weeks after cessation of the 12 FOLFOX regimen 
treatments (postchemotherapy volume). The spleen volume 
ratio was defined as postchemotherapy volume divided by 
presurgery volume. Splenomegaly was defined as a >61% 
increase in spleen volume compared with initial measurements.
Statistical analysis
Differences in clinicopathologic features and volumetric 
changes were analyzed using 2-sided Pearson chi-square test 
or Fisher exact test for categorical variables and a Student 
t-test for continuous variables. To define splenomegaly, cut 
off values of the ratio providing the best separation between 
thrombocytopenia group and normal groups after chemo-
therapy cessation were obtained using receiver operating 
characteristic (ROC) curve analyses (Fig. 2). Exact logistic 
regression for multivariate analysis of factors associated with 
splenomegaly was performed. A P-value < 0.05 was considered 
to indicate statistical significance. All calculations and analysis 
were performed using the IBM SPSS Statistics ver. 23.0 (IBM Co., 
Armonk, NY, USA).
RESULTS
Patient demographics 
Patient characteristics for the 2 groups are in Table 1. No 
significant difference was observed in sex, age, body mass 
index, body surface area (BSA), pathologic stage or tumor 
location.
Spleen volume measurements
Median spleen volume at initial stage before surgery 
(presurgical volume) was 132 cm3 (range, 45–388 cm3) in the 
Korean red ginseng group and 141 cm3 (range, 64–250 cm3) 
in the control group (P = 0.753). All patients in this study 
underwent abdominopelvic computed tomography 3 weeks 
after completion of 12 cycles of FOLFOX chemotherapy. The 
median spleen volume after chemotherapy (postchemotherapy 
volume) was 212 cm3 (range, 95–533 cm3) in the Korean red 
ginseng group and 247 cm3 (range, 84–564 cm3), in the control 
group (P = 0.122). All patients showed increased spleen volume 
after completion of chemotherapy. The median spleen volume 
ratio was 1.38 (range, 1.03–2.81) in the Korean red ginseng group 
and 1.89 (range, 1.13–3.01; P = 0.028) in the control group. 
According to ROC curve for correlation of occurrence of 
thrombocytopenia with spleen volume ratio, 1.61 was set as 
the cutoff value based on Youden index. Thus, we defined 
splenomegaly as a >61% increase in spleen volume compared 
with initial measurements. 
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The rate of splenomegaly was significantly lower in the 
Korean red ginseng group than the control group (28.6% Korean 
red ginseng group vs. 61.9% control group, P = 0.03) (Table 2). 
Blood biochemical parameters
In the Korean red ginseng and control groups, mean values for 
AST, total bilirubin and alkaline phosphatase were significantly 
increased and platelet count was significantly reduced after 
12 cycles of chemotherapy. ALT increased significantly after 
chemotherapy in the control group, but did not significantly 
increase in the Korean red ginseng group (Table 3). 
Factors associated with splenomegaly
No difference was seen in univariate analysis in the rate 
of splenomegaly according to sex, age, body mass index, BSA, 
tumor location, or pathology stage. Thrombocytopenia was 
significantly associated with splenomegaly in univariate 
analysis. In multivariate analysis, consumption of Korean red 
ginseng was associated with reduced incidence of splenomegaly 
(Table 4). 
Table 4. Factors associated with splenomegaly 
Variable No.
Univariate analysis Multivariate analysis
No. (%) P-value OR (95% CI) P-value
Sex
Male 22 9 (40.9) 0.554
Female 20 10 (50)
Age (yr)
<65 26 14 (53.8) 0.153
≥65 16 5 (31.3)
Body mass index (kg/m2)
<25 31 14 (45.2) >0.999a)
≥25 11 5 (45.5)
Body surface area
<1.74 32 14 (43.8) >0.999a)
≥1.74 10 5 (50)
Tumor location
Right colon 14 8 (57.1) 0.273
Left colon 28 11 (39.3)
Stage
II 5 2 (40) >0.999a)
III 37 17 (45.9)
Thrombocytopenia
No 25 7 (28) 0.006 1 0.009
Yes 17 12 (70.6) 7.6 (1.6–34.9)
Korean red ginseng extract
Yes 21 6 (28.6) 0.030 1 0.032
No 21 13 (61.9) 5.1 (1.1–23.3)
OR, odds ratio; CI, confidence interval.
a)Fisher exact test.
Table 5. Prevalence of chemotherapy-induced neutropenia and increased AST/ALT
Variable Korean red ginseng group Control group P-value
Neutropenia ≥ grade 3a) 12 (57.1) 8 (38.1) 0.354
No. of ≥ grade 3a) neutropenia 1 (0–6) 0 (0–3) 0.119b)
No. patients who used G-CSFs 11 (52.4) 6 (28.6) 0.208
Increased AST or ALT ≥ grade 3a) 0 (0) 1 (4.8) >0.999c)
Values are presented as number (%) or median (range).
G-CSFs, granulocyte colony stimulating factors.
a)Based on the Common Terminology Criteria for Adverse Events (CTCAE) v4.0. b)Mann-Whitney U-test. c)Fisher exact test.
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Adverse event during chemotherapy
There was no difference of rate of more than grade 3 neutro-
penia between the 2 groups (57.1% in the Korean red ginseng 
group vs. 38.1% in the control group, P = 0.354). No difference 
was seen on the number of patients who used granulocyte 
colony stimulating factors during the chemotherapy periods 
between the 2 groups. There was only 1 patient in the control 
group who showed more than grade 3 elevated AST or ALT 
(Table 5). 
DISCUSSION
This study demonstrated that adding KRG during chemo-
therapy periods reduced oxaliplatin-mediated splenomegaly 
in colon cancer patients. These outcomes implied that Korean 
red ginseng might protect against sinusoidal injury of the 
liver induced by FOLFOX chemotherapy, although the basic 
pathophysiology should be evaluated.
In managing colorectal cancer with liver metastasis, pre-
operative chemotherapy before resection reduces metastasis 
size, thus enhancing the likelihood of curative resection [20]. 
However, sinusoidal injury of the liver is a well-known adverse 
impact of oxaliplatin, first described by Rubbia-Brandt et al. [8] 
in 2004. Sinusoidal dilatation is significantly correlated with 
an increasing number of oxaliplatin-based chemotherapy cycles 
[7]. Oxaliplatin-induced liver injury (also called sinusoidal 
obstruction syndrome) is related to increased morbidity [21,22]. 
According to our results, Korean red ginseng consumption 
was associated with reduced incidence of splenomegaly after 
FOLFOX chemotherapy. However, the mechanism underlying 
protection by Korean red ginseng against oxaliplatin-mediated 
splenomegaly remains unknown. A recent experimental study 
in a murine model demonstrated molecular pathways affecting 
the progression of SOS by FOLFOX treatment [15]. Endothelial 
damage by administration of a FOLFOX regimen provokes 
a prothrombotic state within the liver with upregulation 
of plasminogen activator inhibitor-1 (PAI-1), von Willebrand 
factor and Factor X. In addition, the study also suggests 
that metallothionein 1, heme oxygenase 1, and superoxide 
dismutase 3, which are genes implicated in the oxidative 
stress, are upregulated. An antioxidant diet using butylated 
hydroxyanisole supplementation, which is associated with 
significantly increased NQO1 expression, reduces severity of 
sinusoidal liver injury [15]. KRG have antioxidant effects in vitro 
and in vivo in human studies [23,24]. In another study, Ki et al. 
[25] reported that KRG inhibits hepatocyte degeneration and 
collagen accumulation by blocking TGFb1 and PAI-1 expression. 
All these mechanisms might have positive effects in protection 
against sinusoidal liver injury. Nevertheless, further studies are 
required to clarify the fundamental protection by Korean red 
ginseng against oxaliplatin-based splenomegaly or ability to 
reduce liver toxicity. 
Many studies investigated the association of oxaliplatin-
based chemotherapy with splenomegaly, but did not use the 
same definition of splenomegaly. Angitapalli et al. [12] used 
splenic index (SI), defined as “splenic length (maximum 
longitudinal dimension) × splenic width (transversely across 
the hilum) × splenic height (cephalocaudal dimension)” 
measured by computed tomography. They defined a significant 
increase in SI as more than 50% increase compared to baseline. 
Several other studies used CT-based volumetry program and 
defined splenomegaly as more than 50% increase from baseline 
volume [11,13,14]. In contrast, Imai et al. [26] reported that 
splenic volume enlargement more than 25% measured by CT-
based volumetry was the only independent predictor of SOS. 
Other clinical factors such as accumulative chemotherapy 
cycle, thrombocytopenia, and interval between completion 
of chemotherapy and surgery were not significant factors in 
multivariate analysis. Our study defined splenomegaly as more 
than 61% increase in splenic volume compared to baseline 
volume. Although this definition is an arbitrary cutoff, the 
value was the most discriminating point by ROC curve for 
differentiating thrombocytopenia events after cessation of 
chemotherapy among our patients. However, the definition of 
splenomegaly should be investigated in a large cohort study.
This study has some limitations. The relatively small number 
of patients and lack of sample size calculation were the main 
weak points. However, as far as we know, the impact of 
Korean red ginseng on protection against oxaliplatin-induced 
splenomegaly has rarely been investigated. Thus, accurately 
measuring the proper sample size for this clinical study was 
practically impossible. 
In conclusion, the addition of KRG to FOLFOX chemotherapy 
could protect against oxaliplatin-mediated splenomegaly in 
colon cancer patients. The fundamental pathway should be 
evaluated in further studies. 
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